Stroke
is the fifth leading cause of death and the most frequent cause of
disability worldwide. Currently, stroke diagnosis is based on
neuroimaging; therefore, the lack of a rapid tool to diagnose stroke is
still a major concern. In addition, therapeutic approaches to combat
ischemic stroke are still scarce, since the only approved therapies are
directed toward restoring blood flow to the affected brain area.
However, due to the reduced time window during which these therapies are
effective
(And tPA is so ineffective; tPA has an appalling failure rate of 88% getting to full recovery.) , few patients benefit from them; therefore, alternative
treatments are urgently needed to reduce stroke brain damage in order to
improve patients’ outcome. The
inflammatory response triggered after
the ischemic event plays an important role in the progression of stroke;
consequently, the study of inflammatory molecules in the acute phase of
stroke has attracted increasing interest in recent decades. Here, we
provide an overview of the inflammatory processes occurring during
ischemic stroke, as well as the potential for these inflammatory
molecules to become stroke biomarkers and the possibility that these
candidates will become interesting neuroprotective
(Stop using neuroprotection, it gives NO sense of urgency.) therapeutic targets
to be blocked or stimulated in order to modulate inflammation after
stroke.
175 references supporting this. Has your stroke hospital implemented anything based on these?
No comments:
Post a Comment